THE MEDICATION APPROACH IN KIDNEY PATIENTS DUE TO MULTIPLE MYELOMA: A LITERATURE REVIEW

Abstract

This systematic review aims to present the therapeutic approach used in the treatment of Myeloma Kidney (RM) and the advantages or disadvantages.  Consequently, to determine which is most beneficial for patients with Multiple Myeloma (MM).  The Cochrane Library, the National Library of Medicine (PubMed), the Virtual Health Library (BVS) and the Directory of Open Access Journals (DOAJ) will be used as data sources in this methodological approach using the terms “multiple myeloma”, “ Kidney Diseases” and “Drug Therapy”, in addition to the Boolean operator "and".  All original articles, randomized or non-randomized clinical trials, case-control studies and correlational studies will be classified.  Additionally, the 2018-2023 publication period will be a prerequisite for inclusion.  Exclusion criteria are: literature review articles, abstracts and meta-analyses.  In this analysis, it was found that, of the 10 studies, 4 studies evaluated the effects of Bortezomib;  3, the effects of daratumumab;  2, Isatuximab effects;  and 1, the effects of Thalidomide in patients with IR due to MM.  Furthermore, 8 studies are clinical trials and 2 are case reports.  Thus, it was observed that the main medication used was Bortezomib and Daratumumab, with recovery of renal function and reduction or absence of the need for dialysis in patients with MM undergoing treatment and reduction of disease progression, with lasting response, respectively.